Schiff Base-Poloxamer P85 Combination Prevents Prostate Cancer Progression in C57/Bl6 Mice
BACKGROUND Prostate cancer which is the second most common cause of death among men has a high incidence in recent years. Current therapeutic regimens should be improved to overcome drug resistance. At the metastatic stage, tumors become refractory to established chemotherapeutic treatments and caus...
Gespeichert in:
| Veröffentlicht in: | The Prostate 2016-11, Vol.76 (15), p.1454-1463 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1463 |
|---|---|
| container_issue | 15 |
| container_start_page | 1454 |
| container_title | The Prostate |
| container_volume | 76 |
| creator | Doğan, Ayşegül Demirci, Selami Türkmen, Neşe Başak Çağlayan, Ahmet Burak Aydın, Safa Telci, Dilek Kılıç, Ertuğrul Şahin, Kazım Orhan, Cemal Tuzcu, Mehmet Ekici, Asiye Işın Doğan Şahin, Fikrettin |
| description | BACKGROUND
Prostate cancer which is the second most common cause of death among men has a high incidence in recent years. Current therapeutic regimens should be improved to overcome drug resistance. At the metastatic stage, tumors become refractory to established chemotherapeutic treatments and cause serious problems at the clinics. Development of new drug molecules that are able to transport through the membrane easily and kill tumor cells rapidly is of great interest.
METHOD
In the current study, a novel Heterodinuclear copper(II)Mn(II) Schiff base complex combined with P85 was used for prostate cancer treatment in vivo. Tramp‐C1 cells injected animals were subjected to chemotherapeutic formulation treatment and results were analyzed by toxicology analysis, tumor volume measurements, and histopathological analysis. 0.5 mg/kg Schiff base was selected and combined with 0.05% P85 according to the toxicology analysis showing the enzyme levels, blood parameters, and multiple organ toxicity.
RESULTS
Results demonstrated that Heterodinuclear copper(II)Mn(II) complex‐P85 combination decreased tumor formation and tumor volume steadily over the course of experiments.
CONCLUSIONS
Overall, Heterodinuclear copper(II)Mn(II) complex‐P85 exerted remarkable anti‐cancer activity in vivo in C57/B16 mice. Prostate 76:1454–1463, 2016. © 2016 Wiley Periodicals, Inc. |
| doi_str_mv | 10.1002/pros.23229 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1827916526</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4188802171</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3939-e6a5beec6266f1b679b9335f4b619ecf7fd2225ebc9cd3a3947bffe597526a363</originalsourceid><addsrcrecordid>eNpd0U1P3DAQBmCrKipb6KU_oIrUC5eAP2J7fSwRBSQKEVCBuFiOdwymSQx2lo9_X4cFDpw8kp93NJpB6DvB2wRjunMXQ9qmjFL1Cc0IVrLEuOKf0QxTicuKMLmOvqZ0i3HmmH5B61QyNueCz9DVmb3xzhW7JkHZhC48mR5i0cx5UYe-9YMZfRiKJsIDDGPKRUijGaGozWAnGMN1hJQm5Iei5nJntxPFH29hE6050yX49vpuoL-_987rg_LoZP-w_nVUWqaYKkEY3gJYQYVwpBVStYox7qpWEAXWSbeglHJorbILZpiqZOsccCU5FYYJtoG2Vn3zHu6XkEbd-2Sh68wAYZk0mVOpiMg6058f6G1YxiFPNykiZW5HsvrxqpZtDwt9F31v4rN-21oGZAUefQfP7_8E6-keerqHfrmHbk5Pzl6qnClXGZ9GeHrPmPhPC8kk1xfH-_q8ai7nxxeNPmX_Ad7iiyE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1821773631</pqid></control><display><type>article</type><title>Schiff Base-Poloxamer P85 Combination Prevents Prostate Cancer Progression in C57/Bl6 Mice</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Doğan, Ayşegül ; Demirci, Selami ; Türkmen, Neşe Başak ; Çağlayan, Ahmet Burak ; Aydın, Safa ; Telci, Dilek ; Kılıç, Ertuğrul ; Şahin, Kazım ; Orhan, Cemal ; Tuzcu, Mehmet ; Ekici, Asiye Işın Doğan ; Şahin, Fikrettin</creator><creatorcontrib>Doğan, Ayşegül ; Demirci, Selami ; Türkmen, Neşe Başak ; Çağlayan, Ahmet Burak ; Aydın, Safa ; Telci, Dilek ; Kılıç, Ertuğrul ; Şahin, Kazım ; Orhan, Cemal ; Tuzcu, Mehmet ; Ekici, Asiye Işın Doğan ; Şahin, Fikrettin</creatorcontrib><description>BACKGROUND
Prostate cancer which is the second most common cause of death among men has a high incidence in recent years. Current therapeutic regimens should be improved to overcome drug resistance. At the metastatic stage, tumors become refractory to established chemotherapeutic treatments and cause serious problems at the clinics. Development of new drug molecules that are able to transport through the membrane easily and kill tumor cells rapidly is of great interest.
METHOD
In the current study, a novel Heterodinuclear copper(II)Mn(II) Schiff base complex combined with P85 was used for prostate cancer treatment in vivo. Tramp‐C1 cells injected animals were subjected to chemotherapeutic formulation treatment and results were analyzed by toxicology analysis, tumor volume measurements, and histopathological analysis. 0.5 mg/kg Schiff base was selected and combined with 0.05% P85 according to the toxicology analysis showing the enzyme levels, blood parameters, and multiple organ toxicity.
RESULTS
Results demonstrated that Heterodinuclear copper(II)Mn(II) complex‐P85 combination decreased tumor formation and tumor volume steadily over the course of experiments.
CONCLUSIONS
Overall, Heterodinuclear copper(II)Mn(II) complex‐P85 exerted remarkable anti‐cancer activity in vivo in C57/B16 mice. Prostate 76:1454–1463, 2016. © 2016 Wiley Periodicals, Inc.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.23229</identifier><identifier>PMID: 27338565</identifier><identifier>CODEN: PRSTDS</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Adenocarcinoma - pathology ; Adenocarcinoma - prevention & control ; Animals ; Cell Line, Tumor ; Disease Models, Animal ; Disease Progression ; Drug Combinations ; Injections, Intraperitoneal ; Male ; Mice ; Mice, Inbred C57BL ; P85 ; pluronic ; Poloxamer - administration & dosage ; Poloxamer - toxicity ; prostate cancer ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - prevention & control ; Schiff base ; Schiff Bases - administration & dosage ; Schiff Bases - toxicity ; tramp-C1 ; Tumor Burden</subject><ispartof>The Prostate, 2016-11, Vol.76 (15), p.1454-1463</ispartof><rights>2016 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3939-e6a5beec6266f1b679b9335f4b619ecf7fd2225ebc9cd3a3947bffe597526a363</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpros.23229$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpros.23229$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27338565$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Doğan, Ayşegül</creatorcontrib><creatorcontrib>Demirci, Selami</creatorcontrib><creatorcontrib>Türkmen, Neşe Başak</creatorcontrib><creatorcontrib>Çağlayan, Ahmet Burak</creatorcontrib><creatorcontrib>Aydın, Safa</creatorcontrib><creatorcontrib>Telci, Dilek</creatorcontrib><creatorcontrib>Kılıç, Ertuğrul</creatorcontrib><creatorcontrib>Şahin, Kazım</creatorcontrib><creatorcontrib>Orhan, Cemal</creatorcontrib><creatorcontrib>Tuzcu, Mehmet</creatorcontrib><creatorcontrib>Ekici, Asiye Işın Doğan</creatorcontrib><creatorcontrib>Şahin, Fikrettin</creatorcontrib><title>Schiff Base-Poloxamer P85 Combination Prevents Prostate Cancer Progression in C57/Bl6 Mice</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>BACKGROUND
Prostate cancer which is the second most common cause of death among men has a high incidence in recent years. Current therapeutic regimens should be improved to overcome drug resistance. At the metastatic stage, tumors become refractory to established chemotherapeutic treatments and cause serious problems at the clinics. Development of new drug molecules that are able to transport through the membrane easily and kill tumor cells rapidly is of great interest.
METHOD
In the current study, a novel Heterodinuclear copper(II)Mn(II) Schiff base complex combined with P85 was used for prostate cancer treatment in vivo. Tramp‐C1 cells injected animals were subjected to chemotherapeutic formulation treatment and results were analyzed by toxicology analysis, tumor volume measurements, and histopathological analysis. 0.5 mg/kg Schiff base was selected and combined with 0.05% P85 according to the toxicology analysis showing the enzyme levels, blood parameters, and multiple organ toxicity.
RESULTS
Results demonstrated that Heterodinuclear copper(II)Mn(II) complex‐P85 combination decreased tumor formation and tumor volume steadily over the course of experiments.
CONCLUSIONS
Overall, Heterodinuclear copper(II)Mn(II) complex‐P85 exerted remarkable anti‐cancer activity in vivo in C57/B16 mice. Prostate 76:1454–1463, 2016. © 2016 Wiley Periodicals, Inc.</description><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - prevention & control</subject><subject>Animals</subject><subject>Cell Line, Tumor</subject><subject>Disease Models, Animal</subject><subject>Disease Progression</subject><subject>Drug Combinations</subject><subject>Injections, Intraperitoneal</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>P85</subject><subject>pluronic</subject><subject>Poloxamer - administration & dosage</subject><subject>Poloxamer - toxicity</subject><subject>prostate cancer</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - prevention & control</subject><subject>Schiff base</subject><subject>Schiff Bases - administration & dosage</subject><subject>Schiff Bases - toxicity</subject><subject>tramp-C1</subject><subject>Tumor Burden</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0U1P3DAQBmCrKipb6KU_oIrUC5eAP2J7fSwRBSQKEVCBuFiOdwymSQx2lo9_X4cFDpw8kp93NJpB6DvB2wRjunMXQ9qmjFL1Cc0IVrLEuOKf0QxTicuKMLmOvqZ0i3HmmH5B61QyNueCz9DVmb3xzhW7JkHZhC48mR5i0cx5UYe-9YMZfRiKJsIDDGPKRUijGaGozWAnGMN1hJQm5Iei5nJntxPFH29hE6050yX49vpuoL-_987rg_LoZP-w_nVUWqaYKkEY3gJYQYVwpBVStYox7qpWEAXWSbeglHJorbILZpiqZOsccCU5FYYJtoG2Vn3zHu6XkEbd-2Sh68wAYZk0mVOpiMg6058f6G1YxiFPNykiZW5HsvrxqpZtDwt9F31v4rN-21oGZAUefQfP7_8E6-keerqHfrmHbk5Pzl6qnClXGZ9GeHrPmPhPC8kk1xfH-_q8ai7nxxeNPmX_Ad7iiyE</recordid><startdate>201611</startdate><enddate>201611</enddate><creator>Doğan, Ayşegül</creator><creator>Demirci, Selami</creator><creator>Türkmen, Neşe Başak</creator><creator>Çağlayan, Ahmet Burak</creator><creator>Aydın, Safa</creator><creator>Telci, Dilek</creator><creator>Kılıç, Ertuğrul</creator><creator>Şahin, Kazım</creator><creator>Orhan, Cemal</creator><creator>Tuzcu, Mehmet</creator><creator>Ekici, Asiye Işın Doğan</creator><creator>Şahin, Fikrettin</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>201611</creationdate><title>Schiff Base-Poloxamer P85 Combination Prevents Prostate Cancer Progression in C57/Bl6 Mice</title><author>Doğan, Ayşegül ; Demirci, Selami ; Türkmen, Neşe Başak ; Çağlayan, Ahmet Burak ; Aydın, Safa ; Telci, Dilek ; Kılıç, Ertuğrul ; Şahin, Kazım ; Orhan, Cemal ; Tuzcu, Mehmet ; Ekici, Asiye Işın Doğan ; Şahin, Fikrettin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3939-e6a5beec6266f1b679b9335f4b619ecf7fd2225ebc9cd3a3947bffe597526a363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - prevention & control</topic><topic>Animals</topic><topic>Cell Line, Tumor</topic><topic>Disease Models, Animal</topic><topic>Disease Progression</topic><topic>Drug Combinations</topic><topic>Injections, Intraperitoneal</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>P85</topic><topic>pluronic</topic><topic>Poloxamer - administration & dosage</topic><topic>Poloxamer - toxicity</topic><topic>prostate cancer</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - prevention & control</topic><topic>Schiff base</topic><topic>Schiff Bases - administration & dosage</topic><topic>Schiff Bases - toxicity</topic><topic>tramp-C1</topic><topic>Tumor Burden</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Doğan, Ayşegül</creatorcontrib><creatorcontrib>Demirci, Selami</creatorcontrib><creatorcontrib>Türkmen, Neşe Başak</creatorcontrib><creatorcontrib>Çağlayan, Ahmet Burak</creatorcontrib><creatorcontrib>Aydın, Safa</creatorcontrib><creatorcontrib>Telci, Dilek</creatorcontrib><creatorcontrib>Kılıç, Ertuğrul</creatorcontrib><creatorcontrib>Şahin, Kazım</creatorcontrib><creatorcontrib>Orhan, Cemal</creatorcontrib><creatorcontrib>Tuzcu, Mehmet</creatorcontrib><creatorcontrib>Ekici, Asiye Işın Doğan</creatorcontrib><creatorcontrib>Şahin, Fikrettin</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Doğan, Ayşegül</au><au>Demirci, Selami</au><au>Türkmen, Neşe Başak</au><au>Çağlayan, Ahmet Burak</au><au>Aydın, Safa</au><au>Telci, Dilek</au><au>Kılıç, Ertuğrul</au><au>Şahin, Kazım</au><au>Orhan, Cemal</au><au>Tuzcu, Mehmet</au><au>Ekici, Asiye Işın Doğan</au><au>Şahin, Fikrettin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Schiff Base-Poloxamer P85 Combination Prevents Prostate Cancer Progression in C57/Bl6 Mice</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>2016-11</date><risdate>2016</risdate><volume>76</volume><issue>15</issue><spage>1454</spage><epage>1463</epage><pages>1454-1463</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><coden>PRSTDS</coden><abstract>BACKGROUND
Prostate cancer which is the second most common cause of death among men has a high incidence in recent years. Current therapeutic regimens should be improved to overcome drug resistance. At the metastatic stage, tumors become refractory to established chemotherapeutic treatments and cause serious problems at the clinics. Development of new drug molecules that are able to transport through the membrane easily and kill tumor cells rapidly is of great interest.
METHOD
In the current study, a novel Heterodinuclear copper(II)Mn(II) Schiff base complex combined with P85 was used for prostate cancer treatment in vivo. Tramp‐C1 cells injected animals were subjected to chemotherapeutic formulation treatment and results were analyzed by toxicology analysis, tumor volume measurements, and histopathological analysis. 0.5 mg/kg Schiff base was selected and combined with 0.05% P85 according to the toxicology analysis showing the enzyme levels, blood parameters, and multiple organ toxicity.
RESULTS
Results demonstrated that Heterodinuclear copper(II)Mn(II) complex‐P85 combination decreased tumor formation and tumor volume steadily over the course of experiments.
CONCLUSIONS
Overall, Heterodinuclear copper(II)Mn(II) complex‐P85 exerted remarkable anti‐cancer activity in vivo in C57/B16 mice. Prostate 76:1454–1463, 2016. © 2016 Wiley Periodicals, Inc.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>27338565</pmid><doi>10.1002/pros.23229</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-4137 |
| ispartof | The Prostate, 2016-11, Vol.76 (15), p.1454-1463 |
| issn | 0270-4137 1097-0045 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1827916526 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adenocarcinoma - pathology Adenocarcinoma - prevention & control Animals Cell Line, Tumor Disease Models, Animal Disease Progression Drug Combinations Injections, Intraperitoneal Male Mice Mice, Inbred C57BL P85 pluronic Poloxamer - administration & dosage Poloxamer - toxicity prostate cancer Prostatic Neoplasms - pathology Prostatic Neoplasms - prevention & control Schiff base Schiff Bases - administration & dosage Schiff Bases - toxicity tramp-C1 Tumor Burden |
| title | Schiff Base-Poloxamer P85 Combination Prevents Prostate Cancer Progression in C57/Bl6 Mice |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T07%3A23%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Schiff%20Base-Poloxamer%20P85%20Combination%20Prevents%20Prostate%20Cancer%20Progression%20in%20C57/Bl6%20Mice&rft.jtitle=The%20Prostate&rft.au=Do%C4%9Fan,%20Ay%C5%9Feg%C3%BCl&rft.date=2016-11&rft.volume=76&rft.issue=15&rft.spage=1454&rft.epage=1463&rft.pages=1454-1463&rft.issn=0270-4137&rft.eissn=1097-0045&rft.coden=PRSTDS&rft_id=info:doi/10.1002/pros.23229&rft_dat=%3Cproquest_pubme%3E4188802171%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1821773631&rft_id=info:pmid/27338565&rfr_iscdi=true |